IP Library › Granted Patent US 12,470,081
Granted Patent B2
US 12,470,081 · App. 18/612,853 · Granted Nov 11, 2025

Power source charging for negative pressure wound therapy apparatus

Inventors: Matthew Ash (Cambridge, GB); Damyn Musgrave (Cottenham, GB); Felix Clarence Quintanar (Hull, GB)
Assignee: Smith & Nephew Asia Pacific Pte. Limited
H02J7/007194H02J7/0048A61M1/962A61M2205/3331A61M2205/583A61M2205/8206A61M2205/8237
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,470,081
App. No.
18/612,853
Granted
Nov 11, 2025
Kind
B2
Abstract

Embodiments of negative pressure wound therapy devices, systems and methods are disclosed. In some embodiments, a negative pressure wound therapy device includes a negative pressure source configured to provide negative pressure to a wound via a fluid flow path, a power source configured to power the negative pressure source, and a charging circuit configured to monitor a temperature of the power source and charge the power source. The charging circuit can be further configured to in response to a determination that the temperature of the power source is below a temperature threshold, provide a first charging power to the power source. The charging circuit can be further configured to in response to a determination that the temperature of the power source has reached or is above the temperature threshold, lower the first charging power to a second charging power.

Claims (71)

1 . A negative pressure wound therapy device comprising:

a negative pressure source configured to provide negative pressure wound therapy to a wound covered by a wound dressing;

a power source configured to provide power to the negative pressure source; and

an electronic processing circuitry configured to:

responsive to a determination that a temperature of the power source is below a first temperature threshold, provide a first charging power to the power source;

responsive to a determination that the temperature of the power source is above the first temperature threshold, provide a second charging power to the power source, the second charging power being lower the first charging power; and

responsive to a determination that the temperature of the power source is below a second temperature threshold, disable provision of power by the power source to the negative pressure source and cause the negative pressure source to cease provision of negative pressure wound therapy to the wound.

2 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is further configured to, while the second charging power is being provided to the power source:

responsive to a determination that the temperature of the power source has fallen below the first temperature threshold, provide the first charging power to the power source.

3 . The negative pressure wound therapy device of claim 1 , wherein the first charging power comprises electrical current at a first level and the second charging power comprises electrical current at a second level that is lower than the first level.

4 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is further configured to stop provision of charging power to the power source responsive to a determination that the power source is substantially charged.

5 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is configured to disable provision of power by the power source to the negative pressure source by isolating the power source from the negative pressure source.

6 . The negative pressure wound therapy device of claim 1 , further comprising a temperature sensor coupled to the electronic processing circuitry and configured to measure the temperature of the power source.

7 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is configured to receive a charging power from a power supply and adjust the charging power to the first or second charging power.

8 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is further configured to a monitor a remaining capacity of the power source and indicate that the remaining capacity has fallen below a threshold indicative of a low capacity.

9 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is further configured to:

responsive to a determination that the temperature of the power source is above a third temperature threshold, disable provision of power by the power source to the negative pressure source and cause the negative pressure source to cease provision of negative pressure wound therapy to the wound,

wherein the second temperature threshold is below the first temperature threshold, and

wherein the third temperature threshold is above the first temperature threshold.

10 . The negative pressure wound therapy device of claim 1 , wherein the electronic processing circuitry is further configured to:

responsive to a determination that the temperature of the power source is above a third temperature threshold, disable provision of power by the power source to the negative pressure source and cause the negative pressure source to cease provision of negative pressure wound therapy to the wound; and

responsive to a determination that the temperature of the power source is between the third temperature threshold and a fourth temperature threshold, disable charging of the power source and cause the power source to continue providing power to the negative pressure source so that the negative pressure source provides negative pressure wound therapy to the wound,

wherein the fourth temperature threshold is above the first temperature threshold and below the third temperature threshold.

11 . The negative pressure wound therapy device of claim 1 , wherein provision of the first or second charging power to the power source causes the power source to continue providing power to the negative pressure source so that the negative pressure source provides negative pressure wound therapy to the wound.

12 . A method of operating a negative pressure wound therapy device, the method comprising, by an electronic processing circuitry:

at a first time:

determining that a temperature a power source is below a first temperature threshold; and

responsive to determining that the temperature of the power source is below the first temperature threshold, providing a first charging power to the power source;

at a second time:

determining that the temperature of the power source is above the first temperature threshold; and

responsive to determining that the temperature of the power source is above the first temperature threshold, providing a second charging power to the power source, the second charging power being lower the first charging power; and

at a third time:

determining that the temperature of the power source is below a second temperature threshold; and

responsive to determining that the temperature of the power source is below the second temperature threshold, disabling provision of power by the power source to a negative pressure source of the negative pressure wound therapy device to cause cessation of provision of negative pressure wound therapy by the negative pressure source.

13 . The method of claim 12 , further comprising, by the electronic processing circuitry:

at a fourth time:

while the second charging power is being provided to the power source:

determining that the temperature of the power source has fallen below the first temperature threshold; and

responsive to determining that the temperature of the power source has fallen below the first temperature threshold, providing the first charging power to the power source.

14 . The method of claim 12 , further comprising, by the electronic processing circuitry:

at a fourth time:

determining that the power source is substantially charged; and

responsive to determining that the power source is substantially charged, stopping provision of charging power to the power source.

15 . The method of claim 12 , wherein disabling provision of power by the power source to the negative pressure source is performed by isolating the power source from the negative pressure source.

16 . The method of claim 12 , further comprising, by the electronic processing circuitry:

receiving a charging power from a power supply and adjusting the charging power to the first or second charging power.

17 . The method of claim 12 , further comprising, by the electronic processing circuitry:

at a fourth time:

determining that a remaining capacity of the power source has fallen below a threshold indicative of a low capacity; and

providing an indication responsive to determining that the remaining capacity has fallen below the threshold indicative of the low capacity.

18 . The method of claim 12 , wherein the method further comprises, by the electronic processing circuitry:

at a fourth time:

determining that the temperature of the power source is above a third temperature threshold; and

responsive to determining that the temperature of the power source is above the third temperature threshold, disabling provision of power byte the power source to the negative pressure source and cause cessation of provision of negative pressure wound therapy,

wherein the second temperature threshold is below the first temperature threshold, and

wherein the third temperature threshold is above the first temperature threshold.

19 . A medical device comprising:

a power source configured to provide power to one or more electronic components including a treatment source configured to provide a therapy; and

an electronic processing circuitry configured to:

responsive to a determination that a temperature of the power source is below a first temperature threshold, provide a first charging power to the power source;

responsive to a determination that the temperature of the power source is above the first temperature threshold, provide a second charging power to the power source, the second charging power being lower the first charging power; and

responsive to a determination that the temperature of the power source is below a second temperature threshold, disable provision of power by the power source to at least the treatment source to cause the treatment source to cease provision of the therapy.

20 . The medical device of claim 19 , wherein the electronic processing circuitry is further configured to, while the second charging power is being provided to the power source:

responsive to a determination that the temperature of the power source has fallen below the first temperature threshold, provide the first charging power to the power source.

21 . The medical device of claim 19 , wherein the electronic processing circuitry is configured to disable provision of power by the power source to at least the treatment source by isolating the power source from the treatment source.

22 . The medical device of claim 19 , wherein the electronic processing circuitry is further configured to stop provision of charging power to the power source responsive to a determination that the power source is substantially charged.

23 . The medical device of claim 19 , wherein the electronic processing circuitry is further configured to a monitor a remaining capacity of the power source and indicate that the remaining capacity has fallen below a threshold indicative of a low capacity.

24 . The medical device of claim 19 , wherein the electronic processing circuitry is further configured to:

responsive to a determination that the temperature of the power source is above a third temperature threshold, disable provision of power by the power source to at least the treatment source and cause the treatment source to cease provision of the therapy,

wherein the second temperature threshold is below the first temperature threshold, and

wherein the third temperature threshold is above the first temperature threshold.

Priority Claims (1)
GB 1806988 · Apr 30, 2018 · national
Continuity (2)
Continuation 17043415
Related Publication 20240305126A1 · Sep 12, 2024
References Cited (198)
US D239019S · Flinn · 1976 [cited by applicant]
US 4328828A · Cianci · 1982 [cited by applicant]
US 4498850A · Perlov et al. · 1985 [cited by applicant]
US 4731076A · Noon et al. · 1988 [cited by applicant]
US D357735S · McPhee · 1995 [cited by applicant]
US 5514088A · Zakko · 1996 [cited by applicant]
US 5712795A · Layman et al. · 1998 [cited by applicant]
US 6027490A · Radford et al. · 2000 [cited by applicant]
US 6203291B1 · Stemme et al. · 2001 [cited by applicant]
US 6232680B1 · Bae et al. · 2001 [cited by applicant]
US 6396407B1 · Kobayashi · 2002 [cited by applicant]
US D475132S · Randolph · 2003 [cited by applicant]
US 7004915B2 · Boynton et al. · 2006 [cited by applicant]
US 7022113B2 · Lockwood et al. · 2006 [cited by applicant]
US 7070584B2 · Johnson et al. · 2006 [cited by applicant]
US 7214202B1 · Vogel et al. · 2007 [cited by applicant]
US D581042S · Randolph et al. · 2008 [cited by applicant]
US D590934S · Randolph et al. · 2009 [cited by applicant]
US D602582S · Pidgeon et al. · 2009 [cited by applicant]
US D602583S · Pidgeon et al. · 2009 [cited by applicant]
US D602584S · Pidgeon et al. · 2009 [cited by applicant]
US 7608066B2 · Vogel · 2009 [cited by applicant]
US 7611500B1 · Lina et al. · 2009 [cited by applicant]
US 7857806B2 · Karpowicz et al. · 2010 [cited by applicant]
US 7927319B2 · Lawhorn · 2011 [cited by applicant]
US 7976598B2 · Matula et al. · 2011 [cited by applicant]
US D645137S · Gonzalez · 2011 [cited by applicant]
US 8021348B2 · Risk, Jr. et al. · 2011 [cited by applicant]
US 8062272B2 · Weston · 2011 [cited by applicant]
US 8066243B2 · Svedman et al. · 2011 [cited by applicant]
US 8070735B2 · Koch et al. · 2011 [cited by applicant]
US D654164S · Cole et al. · 2012 [cited by applicant]
US D660409S · Taggerty et al. · 2012 [cited by applicant]
US 8215929B2 · Shen et al. · 2012 [cited by applicant]
US 8216197B2 · Simmons et al. · 2012 [cited by applicant]
US 8226620B2 · Giezendanner et al. · 2012 [cited by applicant]
US 8308714B2 · Weston et al. · 2012 [cited by applicant]
US 8317774B2 · Adahan · 2012 [cited by applicant]
US 8366692B2 · Weston et al. · 2013 [cited by applicant]
US 8409160B2 · Locke et al. · 2013 [cited by applicant]
US 8480641B2 · Jacobs · 2013 [cited by applicant]
US 8540688B2 · Eckstein et al. · 2013 [cited by applicant]
US 8641693B2 · Locke et al. · 2014 [cited by applicant]
US 8668677B2 · Eckstein et al. · 2014 [cited by applicant]
US 8858517B2 · Pan et al. · 2014 [cited by applicant]
US 8905985B2 · Allen et al. · 2014 [cited by applicant]
US 9050398B2 · Armstrong et al. · 2015 [cited by applicant]
US 9084845B2 · Adie et al. · 2015 [cited by applicant]
US 9138531B2 · Yodfat et al. · 2015 [cited by applicant]
US 9199010B2 · Yao et al. · 2015 [cited by applicant]
US D750222S · Chang · 2016 [cited by applicant]
US D750235S · Maurice · 2016 [cited by applicant]
US D750236S · Maurice · 2016 [cited by applicant]
US D757260S · Lombardi, III et al. · 2016 [cited by applicant]
US 9327063B2 · Locke et al. · 2016 [cited by applicant]
US 9333281B2 · Giezendanner et al. · 2016 [cited by applicant]
US D764047S · Bjelovuk et al. · 2016 [cited by applicant]
US D764048S · Bjelovuk et al. · 2016 [cited by applicant]
US D764653S · Bjelovuk et al. · 2016 [cited by applicant]
US D764654S · Bjelovuk et al. · 2016 [cited by applicant]
US 9415199B2 · Tsai · 2016 [cited by applicant]
US 9427505B2 · Askem et al. · 2016 [cited by applicant]
US D765830S · Bjelovuk et al. · 2016 [cited by applicant]
US 9445948B2 · Smola · 2016 [cited by applicant]
US D773658S · Bow · 2016 [cited by applicant]
US 9586036B2 · Masuda et al. · 2017 [cited by applicant]
US D788293S · Eckstein et al. · 2017 [cited by applicant]
US D791939S · Turturro et al. · 2017 [cited by applicant]
US D792586S · Becker · 2017 [cited by applicant]
US 9737649B2 · Begin et al. · 2017 [cited by applicant]
US D797275S · Evans et al. · 2017 [cited by applicant]
US 9901664B2 · Askem · 2018 [cited by applicant]
US 9923401B2 · Jung · 2018 [cited by applicant]
US 10124093B1 · Francis et al. · 2018 [cited by applicant]
US 10143785B2 · Adams et al. · 2018 [cited by applicant]
US 10155070B2 · Childress et al. · 2018 [cited by applicant]
US D842460S · Gierse et al. · 2019 [cited by applicant]
US D851759S · Jones et al. · 2019 [cited by applicant]
US D852356S · Steele et al. · 2019 [cited by applicant]
US D888225S · Askem · 2020 [cited by applicant]
US 11955829B2 · Ash · 2024 [cited by examiner]
US 20020013545A1 · Soltanpour et al. · 2002 [cited by applicant]
US 20020030002A1 · Verkaart et al. · 2002 [cited by applicant]
US 20020098097A1 · Singh · 2002 [cited by applicant]
US 20020161317A1 · Risk et al. · 2002 [cited by applicant]
US 20040068224A1 · Couvillon, Jr. et al. · 2004 [cited by applicant]
US 20050234485A1 · Seegert et al. · 2005 [cited by applicant]
US 20060281398A1 · Yokomizo et al. · 2006 [cited by applicant]
US 20070219513A1 · Lina et al. · 2007 [cited by applicant]
US 20080005000A1 · Radl et al. · 2008 [cited by applicant]
US 20080234641A1 · Locke et al. · 2008 [cited by applicant]
US 20090085527A1 · Odaohhara · 2009 [cited by examiner]
US 20090216205A1 · Ryan et al. · 2009 [cited by applicant]
US 20090299306A1 · Buan · 2009 [cited by applicant]
US 20100022990A1 · Karpowicz et al. · 2010 [cited by applicant]
US 20100155465A1 · Mollstam et al. · 2010 [cited by applicant]
US 20100244780A1 · Turner et al. · 2010 [cited by applicant]
US 20110006876A1 · Moberg et al. · 2011 [cited by applicant]
US 20110060300A1 · Weig et al. · 2011 [cited by applicant]
US 20110076170A1 · Fujisaki et al. · 2011 [cited by applicant]
US 20110196291A1 · Vischer et al. · 2011 [cited by applicant]
US 20120078181A1 · Smith · 2012 [cited by examiner]
US 20120109083A1 · Coulthard et al. · 2012 [cited by applicant]
US 20120289913A1 · Eckstein et al. · 2012 [cited by applicant]
US 20130012772A1 · Gunday et al. · 2013 [cited by applicant]
US 20130025692A1 · Heide et al. · 2013 [cited by applicant]
US 20130053795A1 · Coulthard et al. · 2013 [cited by applicant]
US 20130131616A1 · Locke · 2013 [cited by applicant]
US 20130237937A1 · Ramella et al. · 2013 [cited by applicant]
US 20130270166A1 · Locke et al. · 2013 [cited by applicant]
US 20130274718A1 · Yao et al. · 2013 [cited by applicant]
US 20140023533A1 · Ishii et al. · 2014 [cited by applicant]
US 20140276488A1 · Locke et al. · 2014 [cited by applicant]
US 20150174320A1 · Grant et al. · 2015 [cited by applicant]
US 20150196765A1 · Marnfeldt · 2015 [cited by examiner]
US 20150231021A1 · Smith et al. · 2015 [cited by applicant]
US 20150246164A1 · Heaton et al. · 2015 [cited by applicant]
US 20150320916A1 · Croteau et al. · 2015 [cited by applicant]
US 20160015872A1 · Luckemeyer et al. · 2016 [cited by applicant]
US 20160015957A1 · Tieck et al. · 2016 [cited by applicant]
US 20160101278A1 · Norris et al. · 2016 [cited by applicant]
US 20160149418A1 · Jung · 2016 [cited by examiner]
US 20160213843A1 · Despa et al. · 2016 [cited by applicant]
US 20160250398A1 · Barr et al. · 2016 [cited by applicant]
US 20160271305A1 · Kurihara et al. · 2016 [cited by applicant]
US 20160303358A1 · Croizat et al. · 2016 [cited by applicant]
US 20170189588A1 · Croizat et al. · 2017 [cited by applicant]
US 20170189666A1 · Sealfon et al. · 2017 [cited by applicant]
US 20170216501A1 · Armstrong et al. · 2017 [cited by applicant]
US 20170224975A1 · Peer et al. · 2017 [cited by applicant]
US 20170296716A1 · Middleton et al. · 2017 [cited by applicant]
US 20170319758A1 · Eddy et al. · 2017 [cited by applicant]
US 20170354767A1 · Carr et al. · 2017 [cited by applicant]
US 20180001000A1 · Herwig et al. · 2018 [cited by applicant]
US 20180021178A1 · Locke · 2018 [cited by examiner]
US 20180104391A1 · Luxon et al. · 2018 [cited by applicant]
US 20180140466A1 · Hunt · 2018 [cited by applicant]
US 20180250459A1 · Kimball et al. · 2018 [cited by applicant]
US 20180318476A1 · Askem et al. · 2018 [cited by applicant]
US 20190021541A1 · Kuempel · 2019 [cited by applicant]
US 20190192744A1 · Greener et al. · 2019 [cited by applicant]
US 20190358372A1 · Askem et al. · 2019 [cited by applicant]
US 20200121833A9 · Askem et al. · 2020 [cited by applicant]
US 20210077670A1 · Long et al. · 2021 [cited by applicant]
US 20210392761A1 · Kitagawa et al. · 2021 [cited by applicant]
US 20240408293A1 · Askem et al. · 2024 [cited by applicant]
DE 102015215165A1 · 2017 [cited by applicant]
EP 0883430B1 · 2007 [cited by applicant]
EP 3124059A1 · 2017 [cited by applicant]
EP 3124060A1 · 2017 [cited by applicant]
FR 2939320A1 · 2010 [cited by applicant]
GB 1220857A · 1971 [cited by applicant]
JP S5647279U · 1981 [cited by applicant]
JP H01101978A · 1989 [cited by applicant]
JP H0796029A · 1995 [cited by applicant]
JP 2007218241A · 2007 [cited by applicant]
JP 6047279B2 · 2016 [cited by applicant]
WO WO0061206A1 · 2000 [cited by applicant]
WO WO03081762A1 · 2003 [cited by applicant]
WO WO2008033788A2 · 2008 [cited by applicant]
WO WO2009071924A1 · 2009 [cited by applicant]
WO WO2011075706A1 · 2011 [cited by applicant]
WO WO2011094410A2 · 2011 [cited by applicant]
WO WO2012004298A1 · 2012 [cited by applicant]
WO WO2012100624A1 · 2012 [cited by applicant]
WO WO2013015827A2 · 2013 [cited by applicant]
WO WO2013064852A1 · 2013 [cited by applicant]
WO WO2013078214A1 · 2013 [cited by applicant]
WO WO2014115819A1 · 2014 [cited by applicant]
WO WO2014164655A1 · 2014 [cited by applicant]
WO WO2015197462A1 · 2015 [cited by applicant]
WO WO2016103031A1 · 2016 [cited by applicant]
WO WO2016109048A1 · 2016 [cited by applicant]
WO WO2017044138A1 · 2017 [cited by applicant]
WO WO2017062042A1 · 2017 [cited by applicant]
WO WO2017160412A1 · 2017 [cited by applicant]
WO WO2017197357A4 · 2018 [cited by applicant]
WO WO2018009873A1 · 2018 [cited by applicant]
WO WO2018009880A1 · 2018 [cited by applicant]
WO WO2018041854A1 · 2018 [cited by applicant]
WO WO2018150263A1 · 2018 [cited by applicant]
WO WO2018150267A2 · 2018 [cited by applicant]
WO WO2018167199A1 · 2018 [cited by applicant]
WO WO2018185101A1 · 2018 [cited by applicant]
WO WO2018195101A1 · 2018 [cited by applicant]
WO WO2019063467A1 · 2019 [cited by applicant]
WO WO2019129581A2 · 2019 [cited by applicant]
WO WO2019139829A1 · 2019 [cited by applicant]
WO WO2019179943A1 · 2019 [cited by applicant]
WO WO2019211730A1 · 2019 [cited by applicant]
WO WO2019211731A1 · 2019 [cited by applicant]
WO WO2019211732A1 · 2019 [cited by applicant]
WO WO2019224059A1 · 2019 [cited by applicant]
WO WO2020011690A1 · 2020 [cited by applicant]
International Preliminary Report on Patentability and Written Opinion for Application No. PCT/IB2019/053507, mailed on Nov. 12, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2019/053507, mailed on Aug. 21, 2019, 10 pages. [cited by applicant]
Jenkins R.W., et al., “Mechanisms of Resistance to Immune Checkpoint Inhibitors,” British Journal of Cancer, Jan. 2, 2018, vol. 118, https://doi.org/10.1038/bjc.2017.434 , pp. 9-16. [cited by applicant]
Wikipedia, “Battery Charger,” retrieved from https://web.archive.org/web/20181109005000/https://en.wikipedia.org/wiki/Battery_charger , on Nov. 9, 2018, 12 pages. [cited by applicant]